Clinical Trial Update: Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating JMT108 Injection for unresectable locally advanced or metastatic malignant melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• JMT108 Injection (JMT-108)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Unresectable Locally Advanced or Metastatic Melanoma | Phase 1, Phase 2 | Status: RECRUITING